Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation
RPRX(NASDAQ:RPRX) NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) will host an Investor Day in New York City today. Senior executives will provide an update on the company’s plans to drive shareholder value creation through its unique business model and capabilities in the large and growing market for funding biopharma innovation with royalties.
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
RPRX(NASDAQ:RPRX) NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:20 p.m. ET.
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
RPRX(NASDAQ:RPRX) NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”):
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
RPRX(NASDAQ:RPRX) NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Zenas BioPharma, Inc. (Nasdaq: ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab.
Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million
RPRXNEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Amgen’s Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from BeOne Medicines for $885 million upfront. The agreement includes an option for BeOne to sell additional Imdelltra royalties to Royalty Pharma for up to $65 million within the next 12 months.
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors
RPRXNEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 and was unanimously appointed as Lead Independent Director in March 2021.
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition With 99.9% Votes Cast In Favor
RPRXRoyalty Pharma Expects 2025 Portfolio Receipts Of $2.975B-$3.125B (Prior $2.9B-$3.05B)
RPRXRoyalty Pharma Q1 Adj. EPS $1.06 Misses $1.59 Estimate,
RPRXRoyalty Pharma Q1 Sales $568.00M Miss $705.34M Estimate
RPRXFDA Approves Second Drug Product Manufacturing Facility For ADSTILADRIN; Ferring Secures Final $200M Payment From Royalty Pharma
RPRXHow Do Investors Really Feel About Royalty Pharma?
RPRXPeering Into Royalty Pharma's Recent Short Interest
RPRXRoyalty Pharma Says It Has Agreed To Acquire Its External Manager, Rp Management, Which Will Generate Cash Savings Of Greater Than $100M In 2026 And Greater Than $175M In 2030; Company Has Approved A New $3B Share Repurchase Program
RPRXReported Earlier, Royalty Pharma Increases Quarterly Dividend By 5% To $0.22/Share, Payable March 10
RPRXRoyalty Pharma Q3 2024 Adj EPS $1.04 Beats $0.93 Estimate
RPRXRoyalty Pharma Raises Full Year 2024 Guidance For Portfolio Receipts From $2.70B - $2.775B To $2.75B - $2.80B
RPRXRoyalty Pharma Q3 Sales $565.00M May Not Be Comparable To $696.10M Estimate
RPRXInsights Ahead: Royalty Pharma's Quarterly Earnings
RPRXRoyalty Pharma Enters $350M Royalty Funding Agreement With Syndax Pharmaceuticals To Support Launches And Development Of Niktimvo And Revumenib, Boosting Proforma Cash To Nearly $800M
RPRXHow To Attend Royalty Pharma Q1 2022 Earnings Conference Call
RPRXRoyalty Pharma (NASDAQ:RPRX) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.
How to Attend Royalty Pharma (RPRX) Conference Call
Follow this link to access the live webcast.
